ArticlePloS one2015

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.

Janaki Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.